Insmed (NASDAQ:INSM) Now Covered by Analysts at Royal Bank of Canada

Research analysts at Royal Bank of Canada initiated coverage on shares of Insmed (NASDAQ:INSM) in a research report issued on Tuesday,Briefing.com Automated Import reports. The firm set an “outperform” rating and a $100.00 price target on the biopharmaceutical company’s stock. Royal Bank of Canada’s price objective indicates a potential upside of 24.95% from the company’s current price.

Other analysts have also recently issued research reports about the stock. Wells Fargo & Company increased their price target on shares of Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a research note on Wednesday, February 19th. Guggenheim raised their target price on shares of Insmed from $95.00 to $101.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. Cantor Fitzgerald restated an “overweight” rating on shares of Insmed in a research note on Wednesday, February 19th. Morgan Stanley raised their target price on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday, February 6th. Finally, Stifel Nicolaus cut their target price on shares of Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a research note on Friday. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $91.60.

Insmed Price Performance

NASDAQ:INSM opened at $80.03 on Tuesday. The firm has a market cap of $14.32 billion, a PE ratio of -14.32 and a beta of 1.11. Insmed has a 12 month low of $21.92 and a 12 month high of $84.91. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The company’s 50-day moving average price is $74.43 and its two-hundred day moving average price is $73.67.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The firm had revenue of $104.44 million during the quarter, compared to the consensus estimate of $102.31 million. On average, equities analysts anticipate that Insmed will post -4.56 EPS for the current fiscal year.

Insider Activity

In other Insmed news, insider Martina M.D. Flammer sold 3,344 shares of Insmed stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $65.91, for a total transaction of $220,403.04. Following the completion of the sale, the insider now owns 102,766 shares of the company’s stock, valued at approximately $6,773,307.06. The trade was a 3.15 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO William Lewis sold 18,750 shares of Insmed stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $81.03, for a total transaction of $1,519,312.50. Following the sale, the chief executive officer now directly owns 334,186 shares of the company’s stock, valued at $27,079,091.58. This represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 532,207 shares of company stock valued at $41,400,465. 4.60% of the stock is currently owned by insiders.

Institutional Trading of Insmed

Institutional investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Insmed by 29.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,215 shares of the biopharmaceutical company’s stock valued at $450,000 after buying an additional 1,402 shares during the period. Nisa Investment Advisors LLC grew its holdings in shares of Insmed by 88.4% in the 3rd quarter. Nisa Investment Advisors LLC now owns 3,350 shares of the biopharmaceutical company’s stock valued at $245,000 after buying an additional 1,572 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in shares of Insmed by 74.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 33,052 shares of the biopharmaceutical company’s stock valued at $2,413,000 after buying an additional 14,110 shares during the period. US Bancorp DE grew its holdings in shares of Insmed by 55.3% in the 3rd quarter. US Bancorp DE now owns 7,932 shares of the biopharmaceutical company’s stock valued at $579,000 after buying an additional 2,824 shares during the period. Finally, Harbor Capital Advisors Inc. bought a new stake in Insmed in the 3rd quarter valued at $1,291,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.